A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®
NCT ID: NCT00391027
Last Updated: 2015-07-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
261 participants
INTERVENTIONAL
2006-12-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
NCT00367445
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
NCT00348374
This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus
NCT00418522
A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®
NCT00356421
A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus
NCT00282971
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Insulin Glargine (Lantus®)
Insulin Glargine (Lantus®)
Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
Inhaled Human Insulin (Exubera®)
Inhaled Human Insulin (Exubera®)
Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Insulin Glargine (Lantus®)
Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
Inhaled Human Insulin (Exubera®)
Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 30 years
Exclusion Criteria
* Smoking
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Bornem, , Belgium
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Genk, , Belgium
Pfizer Investigational Site
Liège, , Belgium
Pfizer Investigational Site
Kuopio, , Finland
Pfizer Investigational Site
Lahti, , Finland
Pfizer Investigational Site
Oulu, , Finland
Pfizer Investigational Site
Besançon, , France
Pfizer Investigational Site
Corbeil-Essonnes, , France
Pfizer Investigational Site
La Rochelle, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Valenciennes, , France
Pfizer Investigational Site
Altenburg, , Germany
Pfizer Investigational Site
Eisenach, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Hohenmölsen, , Germany
Pfizer Investigational Site
Leipzig, , Germany
Pfizer Investigational Site
Neuss, , Germany
Pfizer Investigational Site
Riesa, , Germany
Pfizer Investigational Site
Wangen / Allgaeu, , Germany
Pfizer Investigational Site
's-Hertogenbosch, , Netherlands
Pfizer Investigational Site
Eindhoven, , Netherlands
Pfizer Investigational Site
Nijmegen, , Netherlands
Pfizer Investigational Site
The Hague, , Netherlands
Pfizer Investigational Site
Venlo, , Netherlands
Pfizer Investigational Site
Hønefoss, Buskerud, Norway
Pfizer Investigational Site
Bergen, , Norway
Pfizer Investigational Site
Jessheim, , Norway
Pfizer Investigational Site
Lysaker, , Norway
Pfizer Investigational Site
Skedsmokorset, , Norway
Pfizer Investigational Site
Lodz, , Poland
Pfizer Investigational Site
Lodz, , Poland
Pfizer Investigational Site
Lublin, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Łask, , Poland
Pfizer Investigational Site
A Coruña, A Coruña, Spain
Pfizer Investigational Site
Palma de Mallorca, Balearic Islands, Spain
Pfizer Investigational Site
Huelva, Huelva, Spain
Pfizer Investigational Site
Málaga, Malaga, Spain
Pfizer Investigational Site
Inca, Mallorca, Spain
Pfizer Investigational Site
San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
Pfizer Investigational Site
Alzira, Valencia, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Borås, , Sweden
Pfizer Investigational Site
Eksjö, , Sweden
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Härnösand, , Sweden
Pfizer Investigational Site
Helsingborg, , Sweden
Pfizer Investigational Site
Järfälla, , Sweden
Pfizer Investigational Site
Kristianstad, , Sweden
Pfizer Investigational Site
Linköping, , Sweden
Pfizer Investigational Site
Luleå, , Sweden
Pfizer Investigational Site
Malmo, , Sweden
Pfizer Investigational Site
Motala, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Uddevalla, , Sweden
Pfizer Investigational Site
Umeå, , Sweden
Pfizer Investigational Site
Vaxjo, , Sweden
Pfizer Investigational Site
Bruderholz, , Switzerland
Pfizer Investigational Site
Sankt Gallen, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2171084
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.